Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall vioxxVioxx dosage treatment is no longer available in the United States. On September 30, 2004 Merck, the makers of this COX-2 selective non-steroidal anti-inflammatory (NSAID) prescription drug, voluntarily pulled Vioxx off the shelves. This major recall came after clinical research revealed that patients taking a regular Vioxx dosage for eighteen months were two times more likely to suffer from heart attack or stroke than trial participants who were taking a placebo. Heart attack rate tripled for patients who were taking a Vioxx dosage greater than 25 milligrams.
Prior to the recall of this blockbuster prescription drug, it is estimated that regular Vioxx dosage prescriptions were administered to at least twenty million patients in the United States alone. Vioxx was approved by the FDA in 1999 to treat osteoarthritis, rheumatoid arthritis, primary dysmenorrhea, migraine, and acute pain conditions.
The recommended Vioxx dosage for osteoarthritis was 12.5 mg once daily with a maximum Vioxx dosage at 25 mg. For rheumatoid arthritis, the recommended daily Vioxx dosage was 25 mg. Migraine, acute pain, and primary dysmenorrhea treatment was set at a recommended daily Vioxx dosage of 50 mg that was not to be taken for more than five consecutive days. The lowest Vioxx dosage possible for the treatment of any condition was always recommended to patients and medical professionals.
Prior to the drug''s recall, there were Vioxx warning statements contained in patient product labeling cautioning patients that a Vioxx dosage may interact with other medications. Patients who were concurrently taking Warfarin, Theophylline, Rifampin , lithium, and ACE inhibitors were to be monitored closely, especially during the first few days of treatment. Labeling also cautioned patients and practitioners that certain patient populations may not be good candidates for recommended Vioxx dosage prescriptions.
A Vioxx dosage was developed in response to serious gastrointestinal side effects associated with original NSAIDs. Original NSAIDs, such as ibuprofen and naproxen, had the potential to cause ulcers and other stomach problems. Newer NSAIDs, like Vioxx, Celebrex, and Bextra were created with the hopes of providing pain relief without gastrointestinal side effects. Some clinical trials revealed that these newer drugs caused less stomach irritation, but none of these trials took into account patients who were taking a Vioxx dosage in combination with aspirin.
It is estimated that twenty percent of Vioxx patients were taking a Vioxx dosage in conjunction with low dose aspirin for other medical needs. Aspirin is a known stomach irritant. Merck officials had evidence back in 2001 suggesting that patients who took a Vioxx dosage with aspirin may have gastrointestinal risks equal to patients taking over-the-counter original NSAIDs. Vioxx dosage cardiovascular risks were also called into question at this time, though the drug company made no effort to pursue conclusive evidence about the effects of Vioxx on aspirin users or cardiovascular health. If you, or a loved one, have suffered adverse health reactions from Vioxx dosage treatment, you may be eligible to file a civil lawsuit to recover what you have lost.
Two reports released Wednesday reveal that Merck waged a deceptive promotional campaign for its top-selling painkiller Vioxx and disguised company studies as the work of outside scientists.
JAMA Studies
<...
The third-largest drugmaker in the U.S, Merck, agreed to settle a majority of their claims involving the painkiller Vioxx for $4.85 billion.
The settlement is reportedly the larg...
An Idaho state jury has found that the painkiller Vioxx contributed to the heart attack of a postal worker. The jury awarded him and his wife a multimillion-dollar verdict.
Frede...